Doerte Vossmeyer

Title: Doerte Vossmeyer: Innovator in Integrin Inhibition

Introduction

Doerte Vossmeyer is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit integrins. With a total of 2 patents, Vossmeyer is recognized for his innovative approaches to medical therapies.

Latest Patents

Vossmeyer's latest patents include groundbreaking inventions aimed at inhibiting integrins. The first patent, titled "Compounds for the inhibition of integrins and use thereof," describes a compound of formula (I), where A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene, and the compound serves as an antagonist of the fibronectin receptor alpha5beta1. This invention is particularly useful as an anti-angiogenic agent. The second patent, "Heterocyclic compounds for the inhibition of integrins and use thereof," focuses on compounds of formula (I) that include aromatic heterocyclic 5-membered ring systems. These compounds are designed to inhibit integrins and have potential therapeutic applications.

Career Highlights

Doerte Vossmeyer is currently employed at Shire Orphan Therapies GmbH, where he continues to advance his research in integrin inhibition. His work has positioned him as a key figure in the development of innovative therapies for various medical conditions.

Collaborations

Vossmeyer collaborates with notable colleagues, including Gunther Zischinsky and Roland Stragies. Their combined expertise contributes to the advancement of research in the field of integrin inhibition.

Conclusion

Doerte Vossmeyer is a distinguished inventor whose work in integrin inhibition has the potential to impact medical therapies significantly. His contributions through patents and collaborations highlight his commitment to innovation in biochemistry.